Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

MS trials. The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events. Eligible patients in this trial are now receiving dirucotide on an un-blinded basis to the end of their 27th month in the trial.

Licensing and Development Agreement with Lilly

On December 17, 2007, BioMS entered into a licensing and development agreement (the "Agreement") granting Lilly exclusive worldwide rights to dirucotide. The transaction closed on January 25, 2008 and BioMS received an upfront payment of US $87 million. In September 2008, BioMS received a development milestone payment of US $10 million as a result of the positive interim analysis from the DSMB for MASESTRO-01. BioMS has the potential to receive future development and sales milestones up to US $400 million and escalating royalties on sales if dirucotide is commercialized.

Not later than sixty (60) days following receipt of the final written report of the results of the MAESTRO-01 trial, Lilly shall notify BioMS in writing whether Lilly will terminate the Agreement or alternatively Lilly shall bear 100% of any and all continuing development costs incurred by Lilly or BioMS for dirucotide.

HYC750 and BioCyDex

On May 9, 2008, BioMS entered into a Royalty and Assignment Agreement with Orcrist Bio. Inc. for HYC750, a technology based on hyaluronic acid that has a number of potential therapeutic uses and is being developed as a treatment for the side effects of chemotherapy. BioMS held an exclusive worldwide license to HYC750 from the University of Alberta. As a result of the Royalty and Assignment Agreement, BioMS terminated its license with the University of Alberta and the University entered into
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... building materials using light, developed by researchers at the ... are often considered the realm of science fiction, such ... cloaked starships won,t be a reality for quite some ... materials with building blocks a few billionths of a ... that light flies through them, and works on large ...
(Date:7/28/2014)... , July 28, 2014 Sapphire ... technologies, today announced the appointment of biotechnology veteran ... the board of directors. Levine replaces Cynthia ,CJ, Warner, ... She will remain chairman of the company,s board of ... Sapphire Energy,s mission to deliver commercial scale algae-based fuels ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange ... of health IT to create efficiencies in healthcare information ... Workgroup has developed an issue brief titled, “What ... The HPID Workgroup, a part of WEDI’s Strategic National ... Medicare and Medicaid Services (CMS) to identify common misuse ...
(Date:7/28/2014)... “2014 Deep Research Report ... a professional and in-depth research report on ... introduces Lubricant basic information, including Lubricant definition, ... industry overview. This research covers the international ... well as global industry analysis covering macroeconomic ...
Breaking Biology Technology:Building 'invisible' materials with light 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4
... of Integrated Global Services, CAMBRIDGE, Mass., April ... under a new name, Abt Bio-Pharma Solutions, Inc., ... company will continue to,provide custom strategic, research and ... diagnostics industries,utilizing a team approach that blends decades ...
... 1, 2008 Cardium Therapeutics,(Amex: CXM ... announced today that,InnerCool has entered into a ... a leading distributor of cardiology,medical products. Under ... have,exclusive marketing, sales and distribution rights in ...
... N.J., April 1, 2008 Derma Sciences,Inc (OTC Bulletin ... that sales for 2007 were $34.1 million, an increase ... Gross margins held steady at 34,percent, but due primarily ... the,pipeline, and expanding the Company,s marketing and sales staffs, ...
Cached Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5
(Date:7/28/2014)... About 100 drugs already approved by the U.S. Food ... prevent the growth of certain bacterial pathogens inside human ... Mediterranean spotted fever. The findings, published in mBio ... for Microbiology, demonstrate a new way of identifying non-antibiotic ... , A handful of drugs on the list ...
(Date:7/28/2014)... showing signs of damage from the Deepwater Horizon oil spill ... Gulf of Mexico. The discovery was made by a team ... University. A paper describing this work and additional impacts of ... be published during the last week of July 2014 in ... the National Academy of Sciences . , "The footprint of ...
(Date:7/28/2014)... the South Pole in 1911, but new research shows ... , Using data from 16 ice cores collected from ... South Pole, a group led by Joe McConnell of ... the most accurate and precise reconstruction to date of ... described in an article published today in the online ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... ,This multidisciplinary conference on "Fibrous Protein Nanocomposites for Tailored ... the art in the design, synthesis and characterization of ... applications. The conference will be held in the ... situated at the crossroads of the Mediterranean Sea, exposed ...
... Alejandro Heuck at the University of Massachusetts Amherst recently ... of Health to map the molecular structure of a ... in mammalian cell walls. Once a channel ... plague (Yersinia pestis), dysentery (Shigella), food poisoning (Salmonella) and ...
... - Scientists could take greater strides toward crop improvement ... to understand the mechanisms that allow plants to adapt ... say. In a perspective for the journal ... genetics, and Ivan Baxter, a research computational biologist for ...
Cached Biology News:Fibrous Protein Nanocomposites Conference 2Fibrous Protein Nanocomposites Conference 3UMass Amherst biochemists developing tools to stop plague and other bacterial threats 2UMass Amherst biochemists developing tools to stop plague and other bacterial threats 3Adoption of advanced techniques could propel crop improvement 2
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
... 100%,S-Adenosyl Methionine 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... Assay Range: 0.1 ug/ml to 1 mg/ml,(0.26 M to 2.6 mM) ...
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: